Response to Comments: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

This document is a response-to-comments notice for LCD L39128 concerning amniotic and placental-derived product injections/applications for non-wound musculoskeletal indications. The public comment period ran from 2022-09-01 to 2022-10-15, no comments were received, the notice period began 2023-03-16, and the LCD becomes effective 2023-04-30. No clinical coverage criteria, exclusions, documentation requirements, or frequency limits are specified in this response notice.